

Multiple Pressure Ulcers

With Methicillin-Resistant Staphylococcus aureus (MRSA) Infection



Cost Savings Through the Addition of MIST Therapy® to Standard Wound Care

Background

Pressure ulcers pose a major health problem affecting approximately 3 million adults¹ in the United States. In 2006, over 500,000 hospital admissions were related to pressure ulcers.² While the average hospital stay costs \$10,000², the cost for those admitted primarily for the treatment of a pressure ulcer averages \$37,800.³

For those pressure ulcer patients with antibiotic resistant infections, such as MRSA, treatment costs can be even higher and the problem is growing. In 1972, 2% of staph infections were MRSA, in 2004 this number increased to 63%.⁴

Patient Profile: 66-year-old Female⁵

Conditions: Osteoporosis, cachexia, anemia, chronic pain, and multiple pressure ulcers infected with MRSA.

Care Setting: Long-term Care


Pre-MIST Therapy

Wounds:				
Location	Area	Volume	Stage	Other
Sacrum	37.4 cm ²	3.7 cm ³	IV	3.5 cm tunneling at 8 o'clock
Right Back	2.3 cm ²	1.2 cm ³	IV	Undermining 3.2 cm at 12 o'clock Undermining 2.3 cm from 1 to 2 o'clock
Lower Spine	1.9 cm ²	0.4 cm ³	III	
Right Inner Heel	0.6 cm ²	0.4 cm ³	III	

Treatments: Treatments included negative pressure wound therapy (NPWT) and calcium alginate/silver dressings for 6 months. MIST Therapy was then added two to three times a week.


Post-MIST Therapy

Outcomes: After 6 weeks of MIST Therapy treatment the lower spine and right inner heel wounds closed completely. The sacral wound area reduced by 99.7% (0.1 cm²) and volume by 100% (0.0 cm³) after 4 months and the back ulcer area was reduced by 60% and volume by 92%.



The costs and cost savings depicted in this case study are illustrative only and represent the types of costs that may be incurred by a health care institution. They will vary for each institution, care setting, patient type, treatment course, etc., but provide an outline for consideration and discussion.

Potential Cost Savings: All Four Wounds[†]



The **cost savings** associated with MIST Therapy is the result of its ability to **accelerate wound healing**. In this case study, 6 months of standard wound care treatment was unable to bring these wounds to closure. Six weeks of MIST Therapy treatment brought two of the four wounds to closure, an additional 10 weeks reduced the third and largest wound by 99.7% and the fourth wound area was reduced by 60%, well on its way to complete closure.

* Cost was determined using \$565/week (\$60 canisters, \$36 for dressings, \$469 rental) for negative pressure wound therapy (NPWT) and \$108/week for the silver alginate dressings (assumes 3 dressing changes per week). **Cost for extended care and treatment of infection not included in this analysis.**

** \$250/week was added to the costs of standard care for MIST Therapy (\$125 for applicators, \$125 rental) and silver alginate charges reduced at 6 weeks due to the healing of two of the four wounds.

*** Results with MIST Therapy are not necessarily representative of and may vary with each patient.

† This economic analysis is based upon empirical evidence and has not been derived from a formal cost effectiveness study.

For more case stories related to this topic and others, please contact your local Celleration representative or call (952) 224-8700.



10250 Valley View Road, Suite 137
 Eden Prairie, MN 55344
 phone: 952.224.8700
 fax: 952.224.8750
 customer service: 866.307.MIST (6478)
 email: info@celleration.com

- Luder CH, Ayello EA. Chapter 12. Pressure Ulcers: A Patient Safety Issue. Patient Safety and Quality: An Evidence – Based Handbook for Nurses. Agency for Health Research and Quality. <http://www.ahrq.gov>
- Russo CA, Elixhauser A. Hospitalizations Related to Pressure Sores. 2003 Healthcare Cost and Utilization Project. Rockville, MD: Agency for Healthcare Research and Quality; April 2006. www.hcup-us.ahrq.gov
- Pressure Ulcers Increasing Among Hospital Patients. ARHQ News and Numbers, December 3, 2008. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.ahrq.gov/news/nn/nn120308.htm>
- MRSA in Healthcare Settings. Centers for Disease Control and Prevention, October 3, 2007. http://www.cdc.gov/NCIDOD/DHQP/ar_MRSA_spotlight_2006.html
- Crank E. Treatment of Chronic, Infected Pressure Ulcers with Noncontact, Low-Frequency Ultrasound Therapy. Poster presentation SAWC 2008.

MIST Therapy System FDA Clearance. 510 (k) Clearance June 2005. “The MIST Therapy System produces a low energy ultrasound-generated mist used to promote wound healing through wound cleansing and maintenance debridement by the removal of yellow slough, fibrin, tissue, exudates and bacteria.”

Please see full package insert for additional information on indications, contraindications, warnings, precautions, and side effects.